| |
Thursday, November 5, 1998
Stock option on the anvil at Lupin
Anju Ghangurde
November 4: Lupin Laboratories is believed to have developed a non-infringing process for injectible cephalosporin, cefotaxime, and is on course to seeking a patent for this in the United States. Lupin's move is significant given that the company's US launch of cefotaxime had been stalled by an overriding patent for the product by Takeda, which had extended the effective protection period to 2013.Meanwhile, Lupin also proposes to introduce a stock option plan for its company's permanent employees/working directors as and when the Companies Act permits. It is seeking shareholder approval at its forthcoming AGM to issue not more than 5 per cent of the post issue capital under the scheme. Copyright © 1998 Indian Express Newspapers (Bombay) Ltd.
Related Stories
Lupin, Puerto Rico firm forge alliance
Top
|
|
Printer-friendly page
